CAI
Caris Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.07
−0.99%Sep 2, 2026, 12:30 UTC
Caris Life Sciences announced it will present seven studies advancing precision oncology at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.
Source:Aug 27, 2026, 14:59 UTC
Caris Life Sciences published a study in npj Precision Oncology describing the development and validation of its AI tool, Caris AI Insights, to guide first-line treatment choice for pancreatic cancer.
Source:Aug 5, 2026, 20:05 UTC
Caris Life Sciences reported second quarter 2026 financial results with total revenue of $263.7 million, a 45% increase over the prior year period, and raised its 2026 revenue guidance to $1.03 to $1.04 billion.
Jul 1, 2026, 12:30 UTC
Caris Life Sciences launched Caris Detect, a multi-cancer early detection blood test, in Irving, Texas.
Source:Jun 16, 2026, 12:30 UTC
Caris Life Sciences dual-listed its common stock on NYSE Texas, effective June 17, 2026, while maintaining its primary NASDAQ listing.
Source:Jun 8, 2026, 12:30 UTC
Caris Life Sciences announced a share repurchase program for up to $100 million of its common stock.
Source: